Alopecia areata after hepatitis C virus infection treatment: a case report

Interferon-free direct-acting antiviral (DAA) therapies in the chronic hepatitis C virus (HCV) infections have low side effects. Sofosbuvir / ribavirin (SOF / RBV) therapy combination is among in the currently approved treatment regimens. Aleopecia areata is a very rarely comlication of this treatment. A case of alopecia areata developed after SOF / RBV combination therapy in a patient with chronic hepatitis C infection is presented.

Keywords:

Alopecia areata, hepatitis C virüs sofosbuvir / ribavirin,

PDF

___

Naggie S, Wyles DL. Hepatitis c. In. Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ninth ed. Philadelphia, United States: Elsevier, 2020; 154: 2040-73.
Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017; 66: 1844-52.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
Bal T, Çabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res 2020; 27: 2067-71.
Bakulin IG, Konstantin Z, Vasil Y, et Al. Sofosbuvır Plus ribavirin for the treatment of russian patients with chronic hcv genotype 1 or 3 infection. Hepatology Internatıonal 2015: 9; 52-58.
Kurtaran B, Sarıgül F, Çabalak M. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020; 31: 148-55.
Taliani G, Biliotti E, Capanni M, Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4.
Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and postinterferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779-88.
Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C. Orv Hetil 1998; 139: 2633-7.
Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006; 16: 94-5. 7. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20